Alzheimer's disease (AD) is the most common underlying cause of dementia globally, and the leading cause of years lost to disability in high-income countries as well as the second greatest cause of this worldwide according to the World Health Organization. A defi nite diagnosis of AD can only be established by postmortem studies that demon strate the presence of extracellular amyloid plaques and intracellular tau neurofi brillary tangles [1] . Th e measurement of the neuropathologic hallmarks of AD, namely tau and amyloid beta (Aβ), in cerebrospinal fl uid (CSF) has been shown to be a reliable diagnostic biomarker for AD [2] , but it would be attractive to have less invasive AD biomarkers, such as those that can be measured in plasma. Positron emission tomography (PET) using fl orbetapir-F18 (AV-45) or Pittsburgh Compound-B-C11 (PiB) as radiotracers refl ects fi brillar brain amyloid deposits and is deemed a reliable method to measure brain amyloid plaque burden [3, 4] , but cost and availability of PET biomarker measures are drawbacks associated with this diagnostic strategy. Th erefore, the measurement of Aβ in plasma would be the least invasive and most cost-eff ective biomarker assay. In addition, blood samples could readily be obtained in nonspecialized facilities and sent to specialized laboratories to conduct the measurements. However, published results on the correlation of plasma Aβ with the presence of AD are contradictory and plasma Aβ measurements are subject to more sources of variability than CSF Aβ measurements [5] . Below we will summarize the demographic, biological and technical aspects related to Aβ plasma measures, the results of cross-sectional and longitudinal studies in populations with sporadic AD and AD due to autosomal dominant genetic inheritance, and application of these measurements in clinical trials.
AD, which is modulated by the apolipoprotein E (APOE) genotype [8, 9] .
Th e blood-brain barrier and the blood-CSF barrier regulate the passage of solutes between blood and the central nervous system (CNS), including Aβ. Although there are a number of receptors that are implicated in the infl ux (for example, receptor of advanced glycation end products) and effl ux (for example, low-density lipoprotein receptor, low-density lipoprotein receptor-related protein 1 and 2, P-glycoprotein, low-density and very low-density lipoprotein receptor) of Aβ through the blood-brain barrier, most of the studies that compared plasma Aβ levels with their CSF counterparts [10] [11] [12] [13] or the binding of PET Aβ radiotracers [10, 14] have found no or low correlations between Aβ plasma measurements and CSF Aβ and PET amyloid plaque measurements. On the other hand, CSF and PET values show a high inverse correlation [10, 15, 16] , although CSF ELISA/Luminex assays measure soluble Aβ and PIB/AV-45 PET measure insoluble fi brillar Aβ deposition. However, one study has described a stronger correlation between plasma Aβ and PET PiB measurements [17] .
Origin, distribution and clearance of Aβ in plasma
Th ere are several factors that can explain the low correlation between plasma and CSF Aβ/PET amyloid plaque measurements. First, Aβ species in the CSF and the CNS interstitial fl uid originate in the CNS. CNS Aβ is then thought to diff use from interstitial fl uid into the CSF, while passage of Aβ through the blood-brain barrier is limited. In addition, Aβ in plasma and blood does not originate only in the brain since it also is the product of APP metabolism in skeletal muscle, pancreas, kidney, liver, vascular walls, lung, intestine, skin and several glands and APP can be found in almost all peripheral cells [18] [19] [20] . In addition, most of the Aβ and Aβ in plasma are bound to several proteins (that is, apolipoprotein A-I, A-IV, E and J, α2-macroglobulin, complement factors, immunoglobulins, transthyretin, apoferri tin and serum amyloid P component) and erythrocytes [19, 21] . Finally, platelets are another important source of Aβ and Aβ in plasma [19] and activated platelets release APP and Aβ [22] . Th erefore, it is not surprising that Aβ plasma values may only partially refl ect altered APP metabolism or Aβ in the CNS since there is no evidence that AD is a systemic Aβ amyloidosis. While correlations between undiluted, diluted and cell bound plasma samples have been reported by some investigators to be high, the diagnostic utility of measuring Aβ at diff erent dilutions or in diff erent fractions remains uncertain [23] . Finally, regarding the elimination of plasma Aβ, animal models have implicated the liver as the major organ responsible for the clearance of Aβ from plasma [24] , followed by renal clearance [25] .
Demographic, clinical, genetic and technical issues aff ecting Aβ levels and measurements
Demographic, genetic diagnostic and assay related factors aff ecting Aβ plasma levels Most studies have described a strong association between older age and higher levels of plasma Aβ [10, [26] [27] [28] [29] [30] [31] . Th is association has not been established in Down syndrome (DS) subjects, and there are confl icting results, with some studies fi nding an association [32, 33] and others not [34, 35] . Two studies have evaluated the heritability of Aβ plasma levels. Th e paper by Ertekin-Taner et al. found a higher heritability (54% for Aβ and 73% for Aβ ) [36] than the one by Ibrahim-Verbaas et al. (23% for Aβ and 30% for Aβ ) [37] . None of the studies found that APOE genotype explained a signifi cant amount of the heritability, but the study by Ibrahim-Verbaas et al. found an association between SNPs located at the presenilin 2 gene (PSEN2) and Aβ 1-40 levels. However, some studies have reported an association of lower Aβ in the presence of APOE ε4 alleles [10, 28, 38] and at least one study has described a lower Aβ 1-42 /Aβ 1-40 ratio in non-APOE ε4 subjects in the highest tertile of physical activity [39] . A third study found increased Aβ in young, nondemented fi rst-degree relatives of late onset AD compared to unrelated controls [31] . Other factors associated with Aβ plasma levels are creatinine levels [10, 28, 38, 40] , high density lipoproteins [27] , body mass index [27] , race [38] and sex [38, 41] . One study included age, platelet count, total protein concentration and creatinine levels in a multivariate analysis and found that these variables accounted for 12.9% of plasma levels, underscoring the importance of using multivariable models that adjust for possible confounders [10] . Like CSF levels, plasma levels show a circadian fl uctuation that decreases with aging [11] . Th erefore, standardization of sampling time is important.
Technical aspects regarding sample storage and Aβ plasma measurements
Aβ and Aβ are stable at 2 to 8°C for 6 h but when Aβ is kept at room temperature for 24 h levels drop considerably, exceeding a 20% loss in most of the pools [42] [43] [44] [45] , although ratios of diff erent Aβ species can be more stable [43] . Storage at -20°C is not suitable for longterm storage and Aβ levels are not stable through freezethaw cycles following storage at -20°C, whereas storage at -70°C shows no reductions in Aβ levels for up to three cycles and Aβ levels are stable for at least 12 months when stored at this temperature [42, 45] . One study has reported that some Aβ peptides increase their concentration once frozen [46] . Repeated samples taken during fasting and in the post-prandial state and repeated samples taken from cognitively normal (CN) subjects within three weeks show coeffi cients of variation (CV) that are within the range of the variability of the assay in both cases, indicating that these pre-analytical factors do not have an important eff ect on Aβ measurements [13] . Although not formally tested in plasma, storage in polypropylene tubes currently is the best way to minimize adherence of Aβ to the wall of storage vials compared to polystyrene for CSF samples [47] , and is current practice for plasma samples. Diff erent types of polypropylene are used in the manufacture of biofl uid storage vials, but the eff ects of these diff erences on Aβ levels following shortand long-term storage are not well documented. Finally, collection parameters like collected blood volume and time to freeze have been associated with levels of plasma Aβ [48] and Aβ levels in serum are also less stable than plasma Aβ levels [43] .
Association of Aβ with AD and cerebrovascular disease
Cross-sectional and longitudinal results in DS individuals and subjects harboring autosomal dominant FAD mutations Th e initial study by Scheuner et al. described increased plasma levels of Aβ in subjects from FAD kindreds with pathogenic mutations in the APP, PSEN1 and PSEN2 genes when compared to non-mutation bearing controls [49] and Kosaka et al. found increased plasma levels of Aβ 1-42 when comparing AD patients carrying the βAPP717 mutation to sporadic AD patients [50] . Recently, a cross-sectional cohort of asymptomatic carriers of the PSEN1 E280A mutation had higher Aβ and Aβ 1-42 / Aβ 1-40 than matched CN controls without the mutation [51] .
DS subjects show higher plasma Aβ 1-42 and Aβ 1-40 levels than CN subjects without trisomy 21 [34, 52] . Two studies found no diff erences comparing DS with and without dementia, although an association between Aβ levels and neuropsychological scores in multivariable adjusted models was found [34, 35] . In one of these studies demented DS (dDS) subjects with longer dementia duration showed higher Aβ 1-42 , lower Aβ 1-40 and a higher Aβ 1-42 /Aβ 1-40 ratio than those with shorter dementia duration [35] . Two other studies comparing dDS to cognitively normal DS (cnDS) found a higher Aβ 1-42 / Aβ 1-40 ratio in dDS [53] and increased Aβ 1-40 levels in dDS subjects compared to cnDS that remained stable during a follow-up of several years [54] . Consecutive studies by Schupf et al. [32, 52] have described increased Aβ in dDS when compared to cnDS. Th ese and other studies of plasma Aβ levels in subjects with trisomy 21 and pathogenic FAD mutations are summarized in Table 1 .
Th ere are limited data from prospective studies of plasma Aβ levels in subjects with DS (Table 2 ), but one study described an increased risk of dementia in subjects who at baseline had increased levels of Aβ or Aβ 1-40 [54] . However, in studies conducted by another group, only baseline levels of Aβ were associated with an increased risk of dementia and death [32] . Finally, in a third study, Schupf et al. [33] compared the measurements of the last and baseline visits, fi nding an increased risk of dementia with an increase in Aβ , a decrease in Aβ or a decrease in Aβ 1-42 /Aβ 1-40 ratio with repeated sampling during follow-up.
Cross-sectional results in sporadic AD cases
Results diff er between studies including CN and sporadic AD subjects (Table 3) . Diff erent associations have been reported, with increased levels of Aβ in AD patients [27] , decreased levels of Aβ in AD [14] and increased Aβ in AD [55] . Regarding the gender eff ect, one study found higher Aβ 1-42 levels in women with mild cognitive impairment (MCI) compared to CN women and CN and MCI male subjects [41] .
Some studies classifi ed subjects not only based on clinical diagnosis but also on AD-like CSF profi les for tau and Aβ profi les [10, 13, 56] . In a study that included CN and MCI subjects, the group of CN and MCI subjects with AD-like CSF tau and Aβ profi les showed lower plasma Aβ 1-42 /Aβ 1-40 than CN and MCI subjects with normal CSF tau and Aβ levels [13] . Another study found decreased Aβ and Aβ 1-42 /Aβ 1-40 in MCI and AD subjects with an AD-like CSF tau and Aβ signature when compared to MCI and AD subjects with normal CSF tau and Aβ levels [56] . A more complex association was found for plasma Aβ and Aβ 1-42 levels in the AD Neuroimaging Initiative (ADNI) cohort, showing an interaction between age and diagnostic groups defi ned by an AD-like CSF tau and Aβ profi le [10] . Based on these results, only younger MCI and AD subjects with an ADlike CSF signature showed lower Aβ 1-40 and Aβ values than older MCI and AD subjects with an AD-like CSF signature or subjects with a normal CSF signature. Th ese fi ndings indicate that the presence of AD-like CSF in younger cognitively impaired subjects was what defi ned the group with lower plasma Aβ. Th ere were not enough CN subjects with AD-like CSF to test the association in this group of subjects who are in the pre-symptomatic stage of AD. Although most of these studies do not report sensitivity, specifi city or area under the curve (AUC) measures for plasma Aβ levels, it is clear from these publications that determination of plasma Aβ levels is not useful as a diagnostic classifi er.
Longitudinal results in the CN population and MCI and sporadic AD cases
Diff erent measures of plasma Aβ have been associated with progression to dementia (Table 4) : high baseline Aβ [30, 57] , low baseline Aβ 1-42 /Aβ 1-40 [58, 59] , low baseline Aβ or Aβ [60] , high baseline Aβ 1-40 [29] , high Aβ 1-40 or low Aβ 1-42 /Aβ 1-40 [61] and low Aβ 1-40 in older subjects [62] . Finally, other studies found no associations of plasma Aβ levels with progression to dementia [10, 13, 63] . A study including information on vascular risk factors in midlife and a long follow-up period after baseline plasma sampling found an increased risk of dementia in subjects with low Aβ 1-40 and Aβ 1-42 at baseline and there was an interaction between plasma Aβ levels and diastolic blood pressure that indicated a higher incidence of dementia in subjects with higher diastolic blood pressure and low plasma Aβ levels [60] . One study that compared Aβ plasma levels in CN and MCI subjects who remained cognitively stable or progressed to AD found no diff erences in these two diff erent cohorts [13] , but, as noted above, there were signifi cant diff erences based on the CSF-defi ned groups.
Other studies measuring plasma Aβ levels included correlations of these values with cognitive measures instead of using a diagnosis as outcome. One study included 481 subjects with a long follow-up and repeated measurements, and it used repeated brief telephone interviews for determining the study outcome, and the authors reported greater cognitive decline in subjects with a low Aβ 1-42 /Aβ 1-40 at baseline [64] . However, interassay CV was over 30% (repeated subject measurements were included in the same assay with CV <10%). A larger study of 997 CN subjects followed for 9 years also found a faster cognitive decline in subjects with a lower Aβ 1-42 / Aβ 1-40 at baseline [65] . Cosentino et al. [66] followed 880 subjects for 4.5 years who were CN at baseline or had cognitive impairment that was not severe enough for a dementia diagnosis. In this study, subjects with higher baseline Aβ 1-40 and Aβ and stable or decreasing Aβ 1-42 levels during follow-up had a faster rate of decline, whereas Aβ 1-42 /Aβ showed no such association. On the other hand, in another study by Locascio et al. [67] , the rate of cognitive decline in 122 AD patients was determined in subjects followed for 4.2 years, and these authors described a faster decline in subjects with lower plasma Aβ and Aβ 1-42 at baseline. Two studies found an interaction between cognitive reserve and Aβ plasma levels, indicating that subjects with lower cognitive reserve showed a greater decline associated with Aβ levels [10, 65] .
Longitudinal sampling of Aβ plasma measures
A small number of studies have included repeated sampling of plasma Aβ levels [10, 27, 29, 57] . In the study by Mayeux et al. [27] , a general increase was found for plasma Aβ 1-40 over time, and plasma Aβ 1-40 levels in CN stable subjects showed an increase over time, while incident and baseline AD subjects showed a decrease over time. A second study of the same group reported an increased incidence of dementia in CN subjects who showed a decrease in Aβ 1-42 and Aβ 1-42 /Aβ 1-40 during follow-up [57] . Th e study of Okereke et al. [64] found that a decrease in Aβ 1-42 /Aβ 1-40 in the repeated plasma measurement was associated with greater cognitive decline. Lastly, studies reported by Hansson et al. [29] and Toledo et al. [10] found that during follow-up of 324 subjects for 5 years in the former and 613 subjects for 2 to 3 years in the latter study, there was an increase of Aβ 1-40 and Aβ 1-42 , whereas Aβ 1-42 /Aβ 1-40 decreased.
Aβ plasma measures and cerebrovascular disease
An association between plasma Aβ 1-40 and Aβ 1-42 levels in APOE ε4 carriers and in subjects known to have lacunar infarcts and white matter hyperintensities has been described in the Rotterdam study [28] . A second study that included subjects with cerebral amyloid angiopathy, MCI and AD also found an association between increased Aβ plasma and the presence of white matter hyperintensities and lacunar infarcts [68] . A third study specifi cally analyzed the association between microbleeds and plasma Aβ levels in subjects with AD and vascular dementia [69] . In this study, patients with nonlobar hemor rhages, located in the deep gray matter region and associated with hypertensive vasculopathy, showed higher Aβ 1-40 plasma levels compared to subjects with lobar hemorrhages, which are associated with cerebral amyloid angiopathy. In the ADNI cohort, we found no association between Aβ plasma levels and white matter hyperintensities, but subjects with infarcts on MRI had higher plasma Aβ 1-42 levels [10] . Finally, a longitudinal study by Lambert et al. [59] reported a higher incidence of vascular dementia in subjects with a low Aβ 1-42 /Aβ 1-40 .
Aβ plasma measures as biomarkers in clinical trials
Repeated sampling and measurement of plasma Aβ levels have been used to monitor the pharmacodynamic response of subjects in clinical trials of γ-secretase inhibitors (GSIs) and modulators (GSMs) as well as for passive immunotherapy. Studies in subjects treated with GSIs showed an initial dose-dependent decrease of total Aβ and Aβ 1-40 levels that was followed by a dose-independent increase of both analytes [70, 71] . A model based on a hypothetical inhibition of α-secretase by increases in C99 associated with GSI treatment has been proposed in order to explain these changes, but this remains to be proven [72] . Both studies by Siemers et al. [70, 71] did not report changes in CSF Aβ and Aβ 1-42 levels, although the second sample was taken 4 hours after treatment and a longer timeframe might be needed to assess changes in the CSF levels of these Aβ species. Due to the worse cognitive outcome and secondary eff ects (severe gastrointestinal toxicity, immunomodulation and skin cancer) in patients treated with GSIs [73] , research in this area has shifted towards GSMs that spare Notch signaling. Th ese GSM have also shown a decrease of plasma Aβ [74] [75] [76] but the results regarding any Aβ-rebound are contradictory for GSMs [75, 76] . On the other hand, passive immunotherapy results from clinical trials suggest that there is a dose-dependent transient increase of plasma Aβ in response to the monoclonal anti-Aβ antibody infusion and this was reported to last several weeks [77] . Th us, more research is clearly needed to elucidate the eff ects of these disease-modifying therapies on plasma Aβ levels.
Conclusions
Plasma Aβ is well known to originate in diff erent organs and it also is known that Aβ binds to diff erent proteins and cells in the blood, thereby possibly accounting for why plasma Aβ levels do not correlate with Aβ measured in CSF or CNS plaque burden measured by PET amyloid plaque imaging. Levels of plasma Aβ increase with aging and some clinical associations may change depending on the age of the selected sample. Th e selection of capture antibodies and analytical platforms can have an important impact on the measured Aβ levels; a wide range of mean Aβ 1-40 (214 [15] to 985 pg/ml [40] ) and Aβ 1-42 (36 [15] to 140 pg/ml [19] ) levels in AD patients has been reported in diff erent studies and this also is the case for studies of CN subjects. Moreover, even in studies that use the same analytical platform and capture antibodies, there are important diff erences in the measured Aβ levels, which could be attributed to pre-analytical and analytical factors [10, [42] [43] [44] 48] . A recent study showed that automating multiple pipetting steps in a commercially available immunoassay that measures Aβ 1-42 and Aβ 1-40 provided better precision, thus leading to standardization of reagent dispensing in this test system [48] . Th erefore, standardization eff orts such as this and similar to the ones undertaken in the fi eld of CSF Aβ measurements are needed [47] . Th us, this variability precludes t he possibility of establishing diagnostic or prognostic cut-off s across diff erent studies and populations until these assays are better standardized. Using the profi le of CSF tau and Aβ levels to defi ne groups that have an underlying AD pathology reveals associations between subjects with and without AD-like CSF irrespective of a clinical diagnosis of CN, MCI or AD. Clinical diagnosis in the absence of a neuropathological validation or a CSF Aβ levels/PET plaque load validation may underestimate and confound the diagnostic/prognostic value of plasma Aβ measurements [2] . Cerebrovascular disease, which is a frequent fi nding in aged populations, is another important factor that can aff ect plasma Aβ levels and the prevalence of vascular risk factor and vascular disease varies considerably in the diff erent samples according to the design of the study. While not useful as a diagnostic biomarker as shown by the cross-sectional studies, repeated Aβ plasma measurements in the same individual over time could become useful as a prognostic biomarker. Longitudinal studies favor the 'peripheral sink' hypothesis with a decrease of plasma levels starting in the dementia stage in contrast to an increase of plasma Aβ during the pre-symptomatic stage so that disease stage-specifi c changes later in the course of AD may explain previously described confl icting results. Although the reported diff erences or changes in Aβ plasma levels might not be large enough to predict the longitudinal outcome, it is potentially possible that this biomarker can serve as a prognostic factor or as an endpoint during follow-up of AD patients. However, prospective studies of cohorts with subsequent neuropathology confi rmation of their diagnosis or in concert with data on CSF tau and Aβ levels as well as other biomarker data are needed to establish how to best interpret data on plasma Aβ levels in CN, MCI and AD subjects with and without other comorbid conditions such as cerebrovascular disease.
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